Your browser doesn't support javascript.
loading
CYP2C8-Mediated Formation of a Human Disproportionate Metabolite of the Selective NaV1.7 Inhibitor DS-1971a, a Mixed Cytochrome P450 and Aldehyde Oxidase Substrate.
Asano, Daigo; Hamaue, Syoya; Zahir, Hamim; Shiozawa, Hideyuki; Nishiya, Yumi; Kimura, Takako; Kazui, Miho; Yamamura, Naotoshi; Ikeguchi, Marie; Shibayama, Takahiro; Inoue, Shin-Ichi; Shinozuka, Tsuyoshi; Watanabe, Toshiyuki; Yahara, Chizuko; Watanabe, Nobuaki; Yoshinari, Kouichi.
  • Asano D; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Hamaue S; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Zahir H; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Shiozawa H; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Nishiya Y; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Kimura T; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Kazui M; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Yamamura N; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Ikeguchi M; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Shibayama T; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Inoue SI; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Shinozuka T; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Watanabe T; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Yahara C; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Watanabe N; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
  • Yoshinari K; Drug Metabolism and Pharmacokinetics Research Laboratories (D.A., H.S., Y.N., M.K., N.Y., Ta.S., S.I., C.Y., N.W.), Translational Science Department (M.I.), R&D Planning and Management Department (Ts.S.), and Medicinal Safety Research Laboratories (T.W.), Daiichi Sankyo Co., Ltd., Tokyo, Japan;
Drug Metab Dispos ; 50(3): 235-242, 2022 03.
Article en En | MEDLINE | ID: mdl-34930785
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sulfonamidas / Aldehído Oxidasa Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sulfonamidas / Aldehído Oxidasa Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2022 Tipo del documento: Article